NMTR Average Annual Return Since 2016
Growth of $10,000.00
Without Dividends Reinvested Into NMTR

Also see:
NMTR stock yearly return 2017
NMTR stock yearly return 2018
NMTR stock yearly return 2019
NMTR stock yearly return 2020
NMTR stock yearly return 2021
NMTR stock yearly return 2022
NMTR YTD return
Compare NMTR average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 07/12/2016
End date: 07/25/2023
Start price/share: $67.20
End price/share: $0.07
Dividends collected/share: $0.00
Total return: -99.89%
NMTR Average Annual Return: -62.15%
Starting investment: $10,000.00
Ending investment: $10.72
Years: 7.04

NMTR average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
9 Meters Biopharma is a clinical-stage company focusing on the treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. Co. is deveoping its primary product candidate, vurolenatide for the treatment of SBS, as well as NM-136 for rare obesity disorders. Co. is also developing NM-003 and NM-102 for the treatment of undisclosed rare debilitating digestive diseases with unmet needs and larazotide for the treatment of Multi-system Inflammatory Syndrome through a collaboration with the European Biomedical Research Institute of Salerno, Italy. The NMTR average annual return since 2016 is shown above.

The Average Annual Return on the NMTR average annual return since 2016 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether NMTR average annual return since 2016 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the NMTR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree NMTR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
9 Meters Biopharma (NMTR) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

NOTV Average Annual Return
NOVN Average Annual Return
NPCE Average Annual Return
NRBO Average Annual Return
NRC Average Annual Return
NRIX Average Annual Return
NSPR Average Annual Return
NSTG Average Annual Return
NTLA Average Annual Return
NTRA Average Annual Return
More Healthcare companies »


NMTR Average Annual Return Since 2016 | www.AverageAnnualReturn.com | Copyright © 2021 - 2023, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
Wait! Don't leave yet.
Want to receive our latest research absolutely free?

Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 7.8%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 7.8%.